We remind investors that in Jan 2014, the court upheld the validity of Endo’s patent (5,464,864) on Frova and ruled that it would be infringed by Mylan’s generic version of the treatment. The court ...

Over the weekend, specialty drugmaker Endo Pharmaceuticals (NASDAQ:ENDP) presented more clinical trial results for its already approved migraine treatment, Frova. Frova was initially launched in 2002 ...

Endo, Vernalis Plc Drug Frova FDA Review Period To Be Extended Additional Three Months Endo Pharmaceuticals Holdings Inc. and Vernalis today announced that the U.S. Food and Drug Administration (FDA) ...

CHADDS FORD, PA--(MARKET WIRE)--Apr 7, 2008 -- Endo Pharmaceuticals Inc., a market leader in pain management and a wholly owned subsidiary of Endo Pharmaceuticals Holdings Inc. (NasdaqGS:ENDP - News), ...

Vernalis and partner Endo Pharmaceuticals have reported the results of a second, confirmatory Phase III trial showing the benefits of their Frova product in menstrual migraine. Vernalis and partner ...

NEW YORK, Sept 30 (Reuters) - Endo Pharmaceuticals and Vernalis said on Sunday the U.S. Food and Drug Administration had identified deficiencies and asked for more information regarding their ...

A British drug company said on Monday that a final-stage Phase III study showed that the headache drug Frova helped keep patients free from menstrual-related migraine. Vernalis Plc reported clinical ...

Vernalis of the UK, saw a boost in its share value this morning after reporting positive safety data from a Phase III trial of its migraine drug, Frova (frovatriptan). Vernalis of the UK, saw a boost ...

Jefferson University, Philadelphia, and published today in the journal Neurology, shows that Frova (frovatriptan), a triptan class migraine therapy with a long half life, significantly reduced the ...

Endo Pharma presents results from a Phase 3 randomized, double-blind, placebo-controlled clinical trial evaluating FROVA (frovatriptan succinate) 2.5 mg tablets as a six-day preventative treatment in ...

Elan Corporation plc has received approval from the U.S. Food and Drug Administration for Frova (frovatriptan succinate) 2.5 mg tablets, for the acute treatment of migraine attacks with or without ...